Dr. Reddy's Laboratories Ltd. (RDY)'s Announces the Launch of Ropinirole Hydrochloride XR (Extended-Release) Tablets  
6/7/2012 11:38:37 AM

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE:RDY) announced today that it has launched Ropinirole Hydrochloride XR (Extended-Release) tablets (2 mg, 4 mg, 6 mg, 8mg, and 12 mg), a bioequivalent generic version of REQUIP XL ® tablets in the US market on June 06, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Ropinirole Hydrochloride XR (extended-Release) tablets.